We are pursuing both of these development programs in close collaboration with research groups at the National Institutes of Allergy and Infectious Diseases at the National Institutes of Health.

It is more important to be than to do, for if I am what God wants me to be, then I will do what He wants me to do. If I try to promote a program, however well-meaning, without personal holiness, it will be tainted by the defects of my life. It may lack the direction of full knowledge of the Word, or the discernment of maturity, or the direction that comes through unclouded fellowship with the Lord. Primarily we do not need to develop programs, but people.

We are in initial stages to look at collaboration in biotech and clinical research.

Less than ten per cent of cancer research funding goes to early detection. Our emphasis is on collaboration across technologies and institutions. We have assembled some of the world's leading researchers, including Dr. Brad Nelson from the BC Cancer Agency, to attack early detection in a new collaborative approach.

ASN combines the extensive supplier research assessment and negotiation capabilities of A. T. Kearney with the collaboration, content exchange, and sourcing enablement of UGS technologies and the far reaching business experience and recognized quality services of TCS to offer low-cost country sourcing as a packaged solution.

ASN combines the extensive supplier research assessment and negotiation capabilities of A.T. Kearney with the collaboration, content exchange, and sourcing enablement of UGS technologies and the far reaching business experience and recognized quality services of TCS to offer low-cost country sourcing as a packaged solution.